<SEC-DOCUMENT>0001641172-25-009466.txt : 20250509
<SEC-HEADER>0001641172-25-009466.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250509163110
ACCESSION NUMBER:		0001641172-25-009466
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250509

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pasithea Therapeutics Corp.
		CENTRAL INDEX KEY:			0001841330
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851591963
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92867
		FILM NUMBER:		25930977

	BUSINESS ADDRESS:	
		STREET 1:		1111 LINCOLN ROAD, SUITE 500
		CITY:			MIAMI BEACH
		STATE:			FL
		ZIP:			33139
		BUSINESS PHONE:		(702) 514-4174

	MAIL ADDRESS:	
		STREET 1:		1111 LINCOLN ROAD, SUITE 500
		CITY:			MIAMI BEACH
		STATE:			FL
		ZIP:			33139

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Orca Capital AG
		CENTRAL INDEX KEY:			0002052389
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		SPERLRING 2
		CITY:			PFAFFENHOFEN
		STATE:			2M
		ZIP:			85276
		BUSINESS PHONE:		498441 78644 14

	MAIL ADDRESS:	
		STREET 1:		SPERLRING 2
		CITY:			PFAFFENHOFEN
		STATE:			2M
		ZIP:			85276
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002052389</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>05/06/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001841330</issuerCik>
        <issuerName>Pasithea Therapeutics Corp.</issuerName>
        <issuerCusip>70261F202</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>1111 Lincoln Road</com:street1>
          <com:street2>Suite 500</com:street2>
          <com:city>Miami Beach</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33139</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Orca Capital AG</reportingPersonName>
      <citizenshipOrOrganization>2M</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>371142.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>371142.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>371142.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.7</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 6,529,291 shares of Common Stock outstanding immediately after giving effect to the completion of the Issuer's registered offering and excludes 742,284 shares of Common Stock issuable upon the exercise of warrants held by the Reporting Person, subject to the 4.99% blocker (defined below).

Pursuant to the terms of the warrants as described in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on May 7, 2025, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Common Stock (the "4.99% Blocker").</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Pasithea Therapeutics Corp.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>1111 Lincoln Road, Suite 500, Miami Beach, FLORIDA, 33139.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Orca Capital AG</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Sperlring 2 85276 Hettenshausen Deutschland</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Germany</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>371,142</amountBeneficiallyOwned>
        <classPercent>5.7%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>371,142</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>371,142</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Orca Capital AG</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Thomas Konig</signature>
        <title>Thomas Konig/Director</title>
        <date>05/09/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
